Skip to main content
SpringerLink
Log in
Book cover

Yearbook of Intensive Care and Emergency Medicine 1997 pp 149–157Cite as

Clinical Trials for the Evaluation of Sepsis Therapies

  • Conference paper

Part of the book series: Yearbook of Intensive Care and Emergency Medicine ((YEARBOOK,volume 1997))

Abstract

It is widely acknowledged that sepsis causes substantial morbidity and mortality among the critically ill [1]. Over the years, clinical trials of new therapies for sepsis have failed to find a successful treatment [2–7], yet industry and academia continue to search for the magic bullet cure.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fisher CJ, Agosti JM, Opal SM, et al(1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334: 1697–1702

    Google Scholar 

  2. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653–658

    Article  PubMed  CAS  Google Scholar 

  3. Calandra T, Glauser MP, Schellekens J, Verhoef J (1988) Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 158: 312–319

    Google Scholar 

  4. Greenman RL, Schein RM, Martin MA, et al(1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266: 1097–1102

    Google Scholar 

  5. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al(1991) Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324: 429–436

    Article  PubMed  CAS  Google Scholar 

  6. Knaus WA, Harrel FE, Fisher CJ, et al(1993) The clinical evaluation of new drugs for sepsis: A prospective study design based on survival analysis. JAMA 270: 1233–1241

    Google Scholar 

  7. Fisher CJ, Slotman GJ, Opal SM, et al(1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22: 12–21

    Google Scholar 

  8. Van Dervort AL, Danner RL (1994) Antiendotoxin approaches to septic shock therapy (editorial). Crit Care Med 22: 539–540

    Article  PubMed  Google Scholar 

  9. Bone RC, Fisher CJ, and the Methylprednisolone Severe Sepsis Study Group (1987) Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 92: 1032–1036

    Article  Google Scholar 

  10. Weg JG, Balk RA, Tharratt S, et al(1994) Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 272: 1433–1437

    Article  PubMed  CAS  Google Scholar 

  11. Luce JM (1994) Introduction of new technology into critical care practice: A history of HA-1A human monoclonal antibody against endotoxin. Grit Care Med 21: 1233–1241

    Article  Google Scholar 

  12. Sprung CL, Finch RG, Thijs LG, Glauser MP (1996) International sepsis trial ( INTERSEPT ): Role and impact of a Clinical Evaluation Committee. Crit Care Med 24: 1441–1447

    Google Scholar 

  13. Sibbald WJ, Vincent JL (1995) Round table conference on clinical trials for the treatment of sepsis. Crit Care Med 23: 394–399

    Article  PubMed  CAS  Google Scholar 

  14. Doig GS, Rochon J (1995) Statistical considerations for the design of the optimal clinical trial. In: Vincent JL, Sibbald WJ (eds) Update in Intensive Care and Emergency Medicine Vol 19: Clinical Trials for the Treatment of Sepsis. Springer-Verlag, New York, pp 345–353

    Google Scholar 

  15. Spilker B, Cramer JA (1992) A frame of reference for patient recruitment issues. In: Spilker B, Cramer JA (eds) Patient Recruitment in Clinical Trials. Raven Press, New York, pp 3–23

    Google Scholar 

  16. Meinert CL (1986) Single versus multicenter trials. In: Meinert CL, Tonascia S (eds) Clinical Trials: Design, Conduct and Analysis. Oxford University Press, New York, pp 23–29

    Google Scholar 

  17. Pocock SJ (1983) The size of a clinical trial: Multicenter trials. In: Pocock SJ (ed) Clinical trials: A practical approach. John Wiley and Sons, Chichester, pp 123–142

    Google Scholar 

  18. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864–874

    Article  Google Scholar 

  19. Sibbald WJ, Doig GS, Inman KJ (1995) Sepsis, SIRS and infection. Intensive Care Med 21: 299–301

    Google Scholar 

  20. Seip A, Connolly S, Laupacis A, et al(1990) Systems of logging exclusions in multicenter clinical trials. Society for Clinical Trials Annual Meeting, Toronto (Abst)

    Google Scholar 

  21. Meinert CL (1986) Essential design features of a control clinical trial. In: Meinert CL, Tonascia S (eds) Clinical Trials: Design, Conduct and Analysis. Oxford University Press, New York, pp 65–68

    Google Scholar 

  22. Kreger BE, Craven DE, McCabe WR (1980) Gram-negative bacteremia. Am J Med 68: 344–355

    Article  PubMed  CAS  Google Scholar 

  23. Thijs LG (1995) Fluid therapy in septic shock. In: Vincent JL, Sibbald WJ (eds) Update in Intensive Care and Emergency Medicine Vol 19: Clinical Trials for the Treatment of Sepsis. Springer-Verlag, New York, pp 167–190

    Google Scholar 

  24. Cook DJ, Guyett GH, Laupacis A, Sackett DL (1992) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102 (Suppl): 3055–3115

    Google Scholar 

  25. Cohen J, Carlet J, for the INTERSEPT Study Group (1996) INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Grit Care Med 24: 1431–1440

    Google Scholar 

  26. Bone RC, Balk RA, Fein AM, et al(1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23: 994–1006

    Google Scholar 

  27. Schedel I, Dreikhausen U, Nentwig B, et al(1991) Treatment of Gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Grit Care Med 19: 1104–1113

    Google Scholar 

  28. Dhainaut JA, Tenaillon A, Le Tulzo Y, et al(1994) Platelet activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22: 1720–1728

    Google Scholar 

  29. Fisher CJ, Agosti JM, Opal SM, et al(1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334: 1697–1702

    Google Scholar 

  30. Greenberg RN, Wilson KM, Kunz Ay, et al(1992) Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, Gram-negative sepsis. Crit Care Med 20: 730–735

    Google Scholar 

  31. Abraham E,Wunderink R, Silverman H, et al(1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273: 934–941

    Google Scholar 

  32. McCloskey RV, Straube RC, Sanders C, et al(1994) Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med 121: 1–5

    PubMed  CAS  Google Scholar 

  33. Fisher CJ, Dhainaut JA, Opal SM, et al(1994) Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 271: 1836–1843

    Google Scholar 

Download references

Authors
  1. D. M. Foster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. S. Doig
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care, Erasme Hospital, Free University of Brussels, Route de Lennik 808, B-1070, Brussels, Belgium

    Jean-Louis Vincent (Clinical Director) (Clinical Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Foster, D.M., Doig, G.S. (1997). Clinical Trials for the Evaluation of Sepsis Therapies. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 1997. Yearbook of Intensive Care and Emergency Medicine, vol 1997. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-13450-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-13450-4_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-13452-8

  • Online ISBN: 978-3-662-13450-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation